LLY · 10-Q · 2026Q1 · Full report

Product Revenue - Mounjaro and Zepbound

ELI LILLY & Co · 2026-04-30 · Importance 96 · Surprise 100 · From source text

Mounjaro net product revenue totaled $8,662 million for the three months ended March 31, 2026 (U.S. $4,232 million; Outside U.S. $4,430 million) versus $3,842 million in the prior-year quarter. Zepbound net product revenue totaled approximately $8,294 million for the three months ended March 31, 2026 (U.S. $4,134 million; Outside U.S. $4,160 million) versus $2,312 million in the prior-year quarter. Mounjaro revenue increased substantially year‑over‑year, with U.S. Mounjaro up 59% driven by strong demand partially offset by lower realized prices. Zepbound revenue increased 79% in the U.S. during the quarter, primarily driven by strong demand and partially offset by lower realized prices including announced reductions in cash-pay prices.

Key facts

• Mounjaro revenue increased 59 percent in the U.S. during the three months ended March 31, 2026. source
• Zepbound revenue increased 79 percent in the U.S. during the three months ended March 31, 2026. source
• Revenue outside the U.S. for Mounjaro for the three months ended March 31, 2026 was $4.4 billion compared to $1.2 billion during the three months ended March 31, 2025, primarily driven by volume growth. source
• Mounjaro total revenue for the three months ended March 31, 2026: $8,662 million (U.S. $4,232 million; Outside U.S. $4,430 million). source
• In the U.S. for the three months ended March 31, 2026, the volume increase was primarily driven by Zepbound and Mounjaro, and the lower realized prices were primarily driven by Zepbound and Taltz. source

Impact estimates